FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.
Details
News Market Reaction – FBLG
The recorded move for FBLG in the trading session of this news was +12.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.